» Articles » PMID: 33275730

Neuropathic Pain in Sickle Cell Disease: Measurement and Management

Overview
Specialty Hematology
Date 2020 Dec 4
PMID 33275730
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The identification of chronic pain and neuropathic pain as common contributors to the overall pain experience of patients with sickle cell disease (SCD) has altered the way we should evaluate difficult-to-treat pain. The recognition of these 2 entities is not generally routine among various medical specialties and provider levels that treat SCD. Due to the relative recency with which neuropathic pain was first described in SCD, validated assessment tools and evidence-based treatments remain lacking. Although clinical assessment and judgment must continue to inform all decision making in this understudied area of SCD pain management, a number of validated neuropathic pain assessment tools exist that can make possible a standardized evaluation process. Similarly, investigation of available neuropathic pain treatments for the uniquely complex pain phenotypes of SCD has only just begun and is better established in pain conditions other than SCD. The aim of this review is to briefly summarize the proposed basic pathophysiology, assessment, and treatment of neuropathic pain in patients with SCD. Furthermore, the aim of this review is to encourage an expanded framework for the assessment and treatment of SCD pain that appreciates the hidden complexities of this common complication of SCD.

Citing Articles

Patient and clinician beliefs about potential barriers to treatment of neuropathic pain for adolescents with sickle cell disease.

Rees M, Spraker-Perlman H, Moore R, Lavoie P, Schiff L, Allen J EJHaem. 2024; 5(1):11-20.

PMID: 38406507 PMC: 10887355. DOI: 10.1002/jha2.829.


Feasibility and Acceptability of Online Recruitment and an Online Brief Mindfulness Intervention Among Patients With Sickle Cell Disease.

Ugarte D, Hanley A, Dusek J, Martin S, Cumberland W, Young S Cureus. 2023; 15(2):e35073.

PMID: 36942188 PMC: 10024608. DOI: 10.7759/cureus.35073.


Targeting TRPV1 activity via high-dose capsaicin in patients with sickle cell disease.

Glaros A, Callaghan M, Smith W, Zaidi A EJHaem. 2022; 3(3):653-659.

PMID: 36051054 PMC: 9421981. DOI: 10.1002/jha2.528.


Prevalence of neuropathic pain in adolescents with sickle cell disease: A single-center experience.

Cregan M, Puri L, Guolian Kang , Anghelescu D Pediatr Blood Cancer. 2022; 69(4):e29583.

PMID: 35147289 PMC: 8860881. DOI: 10.1002/pbc.29583.

References
1.
Tran H, Gupta M, Gupta K . Targeting novel mechanisms of pain in sickle cell disease. Blood. 2017; 130(22):2377-2385. PMC: 5709786. DOI: 10.1182/blood-2017-05-782003. View

2.
Field J, Ballas S, Campbell C, Crosby L, Dampier C, Darbari D . AAAPT Diagnostic Criteria for Acute Sickle Cell Disease Pain. J Pain. 2018; 20(7):746-759. DOI: 10.1016/j.jpain.2018.12.003. View

3.
Brandow A, Panepinto J . Clinical Interpretation of Quantitative Sensory Testing as a Measure of Pain Sensitivity in Patients With Sickle Cell Disease. J Pediatr Hematol Oncol. 2016; 38(4):288-93. PMC: 4856159. DOI: 10.1097/MPH.0000000000000532. View

4.
Brandow A, Farley R, Dasgupta M, Hoffmann R, Panepinto J . The use of neuropathic pain drugs in children with sickle cell disease is associated with older age, female sex, and longer length of hospital stay. J Pediatr Hematol Oncol. 2014; 37(1):10-5. PMC: 4270887. DOI: 10.1097/MPH.0000000000000265. View

5.
van der Miesen M, Lindquist M, Wager T . Neuroimaging-based biomarkers for pain: state of the field and current directions. Pain Rep. 2019; 4(4):e751. PMC: 6727991. DOI: 10.1097/PR9.0000000000000751. View